Table 2 Annual Bleeding Rate and laboratory results before and after transition to Emicizumab
From: Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab
Patient number | ABR total Pre-Emicizumab | ABR total Post-Emicizumab | ABR spont.a Pre-Emicizumab | ABR spont.a Post-Emicizumab | ABR traumatic Pre-Emicizumab | ABR traumatic Post-Emicizumab | ABR joint Pre-Emicizumab | ABR joint Post-Emicizumab | Emicizumab (μg/ml) level after 3 doses (3 mg/kg) | Emicizumab level at first follow-up (1.5 mg/kg) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 56.8 | 56.8 |
2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34.4 | 68.4 |
3 | 1 | 0 | 0 | 0 | 1 | 0 | 0.5 | 0 | 51.9 | 51.9 |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49.9 | 75 |
5 | 0.16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37.4 | 66.3 |
6 | 1.5 | 0 | 0.25 | 0 | 1.13 | 0 | 0.5 | 0 | 43.2 | 51.6 |
7 | 0.08 | 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 41.4 | 49.9 |
8 | 0.53 | 0 | 0.16 | 0 | 0.24 | 0 | 0.16 | 0 | 48.4 | 51.8 |
9 | 0.4 | 0.5 | 0.18 | 0 | 0.24 | 0.06 | 0.18 | 0 | 43.7 | 63.5 |
10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35.1 | 56.1 |
11 | 0.33 | 0 | 0.33 | 0 | 0.33 | 0 | 0.33 | 0 | 23.9 | 30.4 |
12 | 0.11 | 0 | 0.18 | 0 | 0 | 0 | 0 | 0 | 39.6 | 38.1 |
13 | 1.55 | 0 | 1 | 0 | 0.27 | 0 | 0.63 | 0 | 52.1 | 41.7 |
Median (Min–Max) | 0.25 (0–4) | 0 (0–0.5)* | 0.05 (0–1) | 0 (0–0)* | 0.23 (0–4) | 0 (0–0.06)* | 0.06 (0–0.63) | 0 (0–0)* | 43.2 (23.9–56.8) | 51.9 (30.4–75) |